252 related articles for article (PubMed ID: 28641169)
1. Association between switching antiepileptic drug products and healthcare utilization: A systematic review.
Kwan P; Palmini A
Epilepsy Behav; 2017 Aug; 73():166-172. PubMed ID: 28641169
[TBL] [Abstract][Full Text] [Related]
2. Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy.
Erickson SC; Le L; Ramsey SD; Solow BK; Zakharyan A; Stockl KM; Harada AS; Curtis B
Epilepsia; 2011 Jul; 52(7):1365-71. PubMed ID: 21692778
[TBL] [Abstract][Full Text] [Related]
3. Generic substitution of antiepileptic drugs: a systematic review of prospective and retrospective studies.
Yamada M; Welty TE
Ann Pharmacother; 2011 Nov; 45(11):1406-15. PubMed ID: 22028417
[TBL] [Abstract][Full Text] [Related]
4. Intrapatient variation in antiepileptic drug plasma concentration after generic substitution vs stable brand-name drug regimens.
Contin M; Alberghini L; Candela C; Benini G; Riva R
Epilepsy Res; 2016 May; 122():79-83. PubMed ID: 26987080
[TBL] [Abstract][Full Text] [Related]
5. Relationship of antiepileptic drugs to generic brittleness in patients with epilepsy.
Das S; Jiang X; Jiang W; Ting TY; Polli JE
Epilepsy Behav; 2020 Apr; 105():106936. PubMed ID: 32092462
[TBL] [Abstract][Full Text] [Related]
6. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy.
LeLorier J; Duh MS; Paradis PE; Lefebvre P; Weiner J; Manjunath R; Sheehy O
Neurology; 2008 May; 70(22 Pt 2):2179-86. PubMed ID: 18505997
[TBL] [Abstract][Full Text] [Related]
7. Switching generic antiepileptic drug manufacturer not linked to seizures: A case-crossover study.
Kesselheim AS; Bykov K; Gagne JJ; Wang SV; Choudhry NK
Neurology; 2016 Oct; 87(17):1796-1801. PubMed ID: 27683844
[TBL] [Abstract][Full Text] [Related]
8. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.
Andermann F; Duh MS; Gosselin A; Paradis PE
Epilepsia; 2007 Mar; 48(3):464-9. PubMed ID: 17346246
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with seizure recurrence in epilepsy patients treated with antiepileptic monotherapy: A retrospective observational cohort study using US administrative insurance claims.
Shcherbakova N; Rascati K; Brown C; Lawson K; Novak S; Richards KM; Yoder L
CNS Drugs; 2014 Nov; 28(11):1047-58. PubMed ID: 25086640
[TBL] [Abstract][Full Text] [Related]
10. Brand name to generic substitution of levetiracetam in patients with epilepsy.
Gha-Hyun L; Dae SJ
Seizure; 2018 Aug; 60():127-131. PubMed ID: 29960217
[TBL] [Abstract][Full Text] [Related]
11. An audit of lamotrigine, levetiracetam and topiramate usage for epilepsy in a district general hospital.
Chappell B; Crawford P
Seizure; 2005 Sep; 14(6):422-8. PubMed ID: 16087359
[TBL] [Abstract][Full Text] [Related]
12. Trends in Antiepileptic Drug Prescriptions for Childhood Epilepsy at a Tertiary Children's Hospital in Korea, 2001-2012.
Cho YS; Ah YM; Jung AH; Kim KJ; Lee JY
Paediatr Drugs; 2015 Dec; 17(6):487-96. PubMed ID: 26400586
[TBL] [Abstract][Full Text] [Related]
13. Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy.
Otoul C; De Smedt H; Stockis A
Epilepsia; 2007 Nov; 48(11):2111-5. PubMed ID: 17651416
[TBL] [Abstract][Full Text] [Related]
14. Current state of the union of epilepsy care in the United States: Antiepileptic drugs - An introduction to the Connectors Project.
Sirven JI; Shafer PO; Kalilani L; Wild I; Fishman J; Owens S
Epilepsy Behav; 2018 Mar; 80():98-103. PubMed ID: 29414565
[TBL] [Abstract][Full Text] [Related]
15. Brand-to-generic levetiracetam switch in patients with epilepsy in a routine clinical setting.
Markoula S; Chatzistefanidis D; Gatzonis S; Siatouni A; Siarava E; Verentzioti A; Kyritsis AP; Patsalos PN
Seizure; 2017 May; 48():1-6. PubMed ID: 28363098
[TBL] [Abstract][Full Text] [Related]
16. Exploring generic brittleness and the demographic factors for its susceptibility in patients with epilepsy.
Das S; Pu X; Jiang X; Jiang W; Tung R; Ting TY; Polli JE
Epilepsy Behav; 2019 Jan; 90():197-203. PubMed ID: 30579779
[TBL] [Abstract][Full Text] [Related]
17. Brand-to-generic oxcarbazepine switch - A prospective observational study.
Bosak M; Słowik A; Dziedzic T
Epilepsy Res; 2019 Mar; 151():75-77. PubMed ID: 30836239
[TBL] [Abstract][Full Text] [Related]
18. Prevalence, utilization, and costs of antiepileptic drugs for epilepsy in Germany--a nationwide population-based study in children and adults.
Hamer HM; Dodel R; Strzelczyk A; Balzer-Geldsetzer M; Reese JP; Schöffski O; Graf W; Schwab S; Knake S; Oertel WH; Rosenow F; Kostev K
J Neurol; 2012 Nov; 259(11):2376-84. PubMed ID: 22544296
[TBL] [Abstract][Full Text] [Related]
19. Psychiatric side effects and antiepileptic drugs: Observations from prospective audits.
Stephen LJ; Wishart A; Brodie MJ
Epilepsy Behav; 2017 Jun; 71(Pt A):73-78. PubMed ID: 28551500
[TBL] [Abstract][Full Text] [Related]
20. Quality of life after switching to generic levetiracetam - A prospective comparative study.
Olsson P; Reimers A; Källén K
Epilepsy Behav; 2019 Jul; 96():169-174. PubMed ID: 31150996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
